36 min listen
Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
ratings:
Length:
49 minutes
Released:
Jul 24, 2023
Format:
Podcast episode
Description
The microbiome therapeutics market has been taking a beating, with several clinical-stage companies failing or flailing at the hands of tough financial markets and regulatory scrutiny. MaaT Pharma Founder & CEO Hervé Affagard knows these perils well. Affagard recently navigated his company through a protracted FDA clinical hold, emerging on the other side with a promising Phase 3 candidate in Graft versus Host Disease. On this episode of the Business of Biotech, Affagard offers a transparent look at how MaaT is beating the odds with a redundant clinical strategy and scrupulous cash management.Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Released:
Jul 24, 2023
Format:
Podcast episode
Titles in the series (100)
005: Building A Biotech All-Star Team With Vivek Ramaswamy by Business Of Biotech